Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2019 - 07 - 10
点击次数: 0
Positions: Vice President, Business Development
Company: Innovent Biologics, Inc.
个人简介:
Blake Salisbury currently leads BD activities as the VP of Business Development at Innovent Biologics, a China based innovative biopharmaceutical company.  Blake has 27 years of experience in pharma/biotech, primarily in business development (20 years), but also in sales, marketing, and pricing. While at Innovent, Blake has in-licensed and out-licensed various early stage assets to/from partners in China, he led a global co-development deal to develop and commercialize a bispecific antibody with Hanmi Pharmaceuticals, and in 2018 he in-licensed 3 late stage oncology small molecules from Incyte for the China market. Prior to joining Innovent, Blake spent almost 24 years with Eli Lilly and Company where he closed over 50 transactions of various types, many of which were notable transactions with Chinese companies, starting as early as 2006.  Blake’s last position at Lilly was as a Senior Director of Corporate Business Development – responsible for in-license, out-license, and M&A activities supporting Lilly’s various Business Units.
发布时间: 2019 - 07 - 10
点击次数: 0
Positions: Chairman & CEO
Company: Akeso Biopharma Inc.
个人简介:
国家“千人计划”专家、科技部创新创业人才、广东省特支计划创业领军人才。现任康方生物医药有限公司董事长、总裁兼首席执行官。拥有20余年学术界和生物制药工业界的从业经历,是药物发现、抗体生产工艺开发及规模化生产专家。曾任职德国拜耳、美国PDL生物制药(现艾伯维)、美国Celera Genomics等个欧美制药公司,负责或参与了多个新药的临床前研究、抗体新药的生产工艺开发和GMP规模化生产。2008年加入中美冠科生物技术有限公司担任生物制药部资深副总裁,作为辉瑞-亚洲癌症研究中心负责人,成功领导了全球第一例跨国制药公司抗体新药研发在中国的整体合作项目。2012年创建中山康方生物医药有限公司,并成功领导国内首例由创新型生物科技公司将完全自主研发的单克隆抗体新药授权给全球制药巨头美国默沙东,实现国产创新抗体药物在海外市场的新突破。康方生物专注于开发有自主知识产权的抗体一类新药,目前已有8个抗体新药进入临床研究阶段,包括国际首创的PD-1双功能抗体。夏博士拥有中山大学生物化学本科学位,是硕士保送生;获英国政府奖学金赴英留学,在纽卡斯尔大学(The University of Newcastle upon Tyne)获得博士学位,并在英国格拉斯哥大学(University of Glasgow)和美国路易斯维尔大学(University of Lousiville)医学院从事生物化学、免疫学及癌症免疫疗法的研究。
发布时间: 2019 - 07 - 10
点击次数: 0
Positions: CEO
Company: Bio-Thera Solutions, Ltd
个人简介:
Shengfeng Li founded Bio-Thera in 2003, and has served since that time as Chief Executive Officer and as a member of our Board of Directors. Prior to founding Bio-Thera, Dr. Li was a founder and founding Chief Scientific Officer of Abmaxis, Inc., California (acquired by Merck). Prior to co-founding Abmaxis, he was employed at Cor Therapeutics, (merged with Millennium). Dr. Li received his Ph.D. in Microbiology from the University of Georgia in 1991, and afterwards, he worked as a postdoctoral scientist and later as a Donoghue Foundation fellow at Yale, where he identified several Raf kinase signaling regulatory molecules such as RKIP and 14-3-3 family of proteins. Dr. Li is an author on multiple publications in peer reviewed journals such as Nature, EMBO, Gene & Dev, and PNAS. He is an inventor on over 20 patents in the areas of target identification, drug discovery, antibody engineering, and product development.
发布时间: 2019 - 07 - 10
点击次数: 0
Positions: Head of External Innovation China
Company: Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd.
个人简介:
Dr. Chen Chen (Michael) currently works as Head of External Innovation China and APAC for Merck KGaA. Michael leads collaborations with academic institutions and local pharmaceutical companies in China and APAC areas with alignment of Merck R&D focus and requirement. He encompasses scouting and evaluation of external opportunities including assets from discovery to clinical development stages, new drug target/biomarker findings, and novel discovery technologies, through open innovation, licensing, co-development, investment and other collaboration models. He also provides his duties within Merck global BD team for various internalization and externalization opportunities. Michael received his bachelor degree in cell and molecular biology from University of Essex, a master degree in cancer immunotherapy from University of Nottingham and a PhD in Biochemistry from Imperial College London. Before joining Merck, he has been leading research projects at Spirogen Ltd./MedImmune, and involved in business development/investment activities at WuXi AppTec and ChemPartner.